Table 3.
Imaging and Laboratory Data (n = 80)⁎
| Variables | Values |
|---|---|
| Plain Films† | |
| Normal | 26 (35.14%) |
| Periosteal reaction/sclerosis | 17 (22.97%) |
| Lytic lesion | 16 (21.62%) |
| Mixed findings (Osteolysis and hyperostosis) | 9 (12.16%) |
| Abnormal structure (dysplasia, scoliosis, ruptured disc) | 5 (6.76%) |
| Hyperostosis | 2 (2.7%) |
| MRI | |
| Received MRI | 79 (98.75%) |
| Received Whole-Body MRI | 55 (69.62%) ‡ |
| Received bone scintigraphy | 25 (31.25%) |
| Received PET-CT | 4 (5%) |
| Bones involved on imaging at diagnosis, median (IQR) | 3 (1 - 5) |
| Bones involved on imaging at last follow up, median (IQR) | 1 (0.75 - 3) § |
| Symmetric lesions | 33 (44.59%) |
| Unifocal | 15 (18.75%) |
| Progressed to multifocal | 4 (26.67%)¶ |
| Findings at Diagnosis‡ | |
| Marrow edema | 57 (72.15%) |
| Periosteal reaction | 18 (22.78%) |
| Osteitis | 15 (18.99%) |
| Soft tissue involvement | 14 (17.72%) |
| Hyperostosis | 6 (7.59%) |
| Lytic lesion | 5 (6.33%) |
| Sclerosis | 4 (5.06%) |
| Labs | |
| Hgb at diagnosis, g/dL, median (IQR) | 12.3 (11.8 - 12.9) |
| WBC at diagnosis, WBC/µL. mean ± SD | 8.48 ± 2 |
| CRP at diagnosis, mg/L, median (IQR) | 8.8 (1.55 - 15.6) |
| ESR at diagnosis, mm/hr, median (IQR) | 21 (9 - 38) |
| CRP at last follow up, mg/L, median (IQR) | 0.5 (0.5 - 3.85) § |
| ESR at last follow up, mm/hr, median (IQR) | 7 (2 - 14) § |
| HLA + | 6 (23.08%) # |
| ANA + | 9 (40.91%)⁎⁎ |
| Received Bone Biopsy | 60 (75%) |
| Normal | 22 (36.67%) †† |
| Inflammation | 28 (46.67%) †† |
| Fibrosis | 10 (16.67%) †† |
⁎
Unless specified, values represent the number (%) of patients; MRI = Magnetic Resonance Imaging; PET-CT = Positron Emission Tomography-Computed Tomography; CRP = C-reactive Protein; ESR = Erythrocyte Sediment Rate; Hgb = Hemoglobin; WBC = White Blood Count; HLA = Human Leukocyte Antigen; ANA = Antinuclear Antibody
†
n = 74
‡
n = 79
§
P < 0.001 by Wilcoxon signed rank test
¶
n = 15
⁎⁎
n = 22
††
n = 60
#
n = 26.